Altimmune to present pemvidutide clinical data at upcoming global nash congress may 27, 2022

Gaithersburg, md., may 20, 2022 (globe newswire) --  altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that dr. scott harris, chief medical officer at altimmune, will give an oral presentation at the 5th global nash congress on may 26-27, 2022, in london, uk. his presentation will provide an overview of pemvidutide, the company's novel, investigational glp-1/glucagon dual receptor agonist under development for the treatment of obesity and nash. dr. harris will also moderate a panel discussion on clinical endpoints in nash trials.
ALT Ratings Summary
ALT Quant Ranking